Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anticancer monoclonal antibodies - MabVax/MSKCC

Next Previous
Drug Profile

Research programme: anticancer monoclonal antibodies - MabVax/MSKCC

Alternative Names: 1B7; 1B7/31F; Anti-GD2 antibodies - MabVax Therapeutics; HuMab-1B7; HuMab-31F9; HuMab-Tn; r5B1

Latest Information Update: 28 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MabVax Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; GD2 ganglioside inhibitors; Tumour-associated carbohydrate antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Nov 2019 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 09 May 2019 BioNTech acquires pre-clinical antibody assets from MabVax Therapeutics
  • 09 Jul 2018 Monoclonal antibodies targetting glycans (Thomsen-nouveau (Tn) and the sialyl Tn (sTn) carbohydrate antigens) licensed to Boehringer ingelheim
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top